Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
S102392-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $31.90 | |
S102392-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $129.90 |
Protein kinase inhibitor
Synonyms | staurosporine|Staurosporin|62996-74-1|(+)-Staurosporine|Antibiotic 230|Antibiotic AM 2282|AM-2282|CCRIS 3272|Antibiotic AM-2282|Alkaloid AM-2282 from Streptomyces|(5S,6R,7R,9R)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Staurosporine (Stsp) is potent inhibitor of protein kinase C (PKC) from rat brain, exhibiting an IC50 value of 2.7 nM. It inhibits rat recombinant PKC-α approximately 100- and 1,000-fold better than PKC-δ and PKC-ζ, respectively.2 However, Stsp is non-sel |
Storage Temp | Store at 2-8°C |
Shipped In | Wet ice |
Grade | Moligand™ |
Action Type | ALLOSTERIC MODULATOR, INHIBITOR |
Mechanism of action | Inhibitor of calcium/calmodulin-dependent protein kinase II beta subunit;Inhibitor of death associated protein kinase 1;Inhibitor of homeodomain interacting protein kinase 1;Inhibitor of mitogen-activated protein kinase kinase 4;Inhibitor of mitogen-activ |
Note | This product is supplied in one (or more) pack size which is freeze dried. Therefore the contents may not be readily visible, as they can coat the bottom or walls of the vial. Please see our FAQs and information page for more details on handling. Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM). Phase 3. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one |
---|---|
INCHI | InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1 |
InChi Key | HKSZLNNOFSGOKW-FYTWVXJKSA-N |
Canonical SMILES | CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC |
Isomeric SMILES | C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC |
WGK Germany | 3 |
PubChem CID | 44259 |
Molecular Weight | 466.53 |
Beilstein | 1060573 |
PubChem CID | 44259 |
---|---|
ChEBI | CHEBI:15738 |
CAS Registry No. | 62996-74-1 |
ChEMBL Ligand | CHEMBL388978 |
BindingDB Ligand | 2579 |
Wikipedia | Staurosporine |
DrugBank Ligand | DB02010 |
DiscoveRx TREEspot | Staurosporine| |
RCSB PDB Ligand | STU |
GPCRdb Ligand | staurosporine |
Enter Lot Number to search for COA:
Pictogram(s) | GHS06, GHS08, GHS09, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H351:Suspected of causing cancer H373:Causes damage to organs through prolonged or repeated exposure H413:May cause long lasting harmful effects to aquatic life H302:Harmful if swallowed H228:Flammable solid H400:Very toxic to aquatic life H410:Very toxic to aquatic life with long lasting effects H300:Fatal if swallowed H310:Fatal in contact with skin H340:May cause genetic defects H350:May cause cancer H361:Suspected of damaging fertility or the unborn child H361d:Suspected of damaging the unborn child |
Precautionary Statements | P273:Avoid release to the environment. P280:Wear protective gloves/protective clothing/eye protection/face protection. P370+P378:In case of fire: Use ... to extinguish. P210:Keep away from heat, hot surface, sparks, open flames and other ignition sources. - No smoking. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P240:Ground/bond container and receiving equipment. P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P281:Use personal protective equipment as required. P241:Use explosion-proof [electrical/ventilating/lighting/.../] equipment. P270:Do not eat, drink or smoke when using this product. P391:Collect spillage. P330:Rinse mouth. P262:Do not get in eyes, on skin, or on clothing. P361+P364:Take off immediately all contaminated clothing and wash it before reuse. P203:Obtain, read and follow all safety instructions before use. P301+P316:IF SWALLOWED: Get emergency medical help immediately. P301+P317:IF SWALLOWED: Get medical help. P318:if exposed or concerned, get medical advice. P316:Get emergency medical help immediately. P319:Get medical help if you feel unwell. |
WGK Germany | 3 |
1. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchya H, Takahashi Y, Masuma R. (1977) A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization.. J Antibiot, 30 (4): (275-82). [PMID:863788] |
2. Rüegg UT, Burgess GM. (1989) Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases.. Trends Pharmacol Sci, 10 (6): (218-20). [PMID:2672462] |
3. Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, Ozato K, Sims 3rd RJ, Singer DS. (2012) BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain.. Proc Natl Acad Sci USA, 109 (18): (6927-32). [PMID:22509028] |
4. Sanders DW, Jumper CC, Ackerman PJ, Bracha D, Donlic A, Kim H, Kenney D, Castello-Serrano I, Suzuki S, Tamura T et al.. (2021) SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation.. Elife, 10 (3): (589-97). [PMID:33890572] |
5. Budworth J, Gescher A. (1995) Differential inhibition of cytosolic and membrane-derived protein kinase C activity by staurosporine and other kinase inhibitors.. FEBS Lett, 362 (2): (139-42). [PMID:7536688] |
6. McKenzie BA et al.. (2020) Activation of the executioner caspases-3 and -7 promotes microglial pyroptosis in models of multiple sclerosis.. J Neuroinflammation, 17 (253). [PMID:32861242] |
7. Lotsberg ML et al.. (2020) AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.. J Thorac Oncol, 15 (6): (973-999). [PMID:32018052] |
8. Wu N et al.. (2021) Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway.. Biofactors, 47 (4): (587-599). [PMID:33740285] |
9. Hofmann L et al.. (2018) Characterization of small fiber pathology in a mouse model of Fabry disease.. Elife, 7 [PMID:30328411] |
10. Tomasek T et al.. (2021) Cell-free hemoglobin-mediated human lung microvascular endothelial barrier dysfunction is not mediated by cell death.. Biochem Biophys Res Commun, 556 (199-206). [PMID:33848934] |
11. Pacitto R et al.. (2017) CXCL12-induced macropinocytosis modulates two distinct pathways to activate mTORC1 in macrophages.. J Leukoc Biol, 101 (3): (683-692). [PMID:28250113] |
12. Toth K et al.. (2019) Encoding the ß-Arrestin Trafficking Fate of Ghrelin Receptor GHSR1a: C-Tail-Independent Molecular Determinants in GPCRs.. ACS Pharmacol Transl Sci, 2 (4): (230-246). [PMID:32259059] |
13. Bhattacharyya M et al.. (2020) Flexible linkers in CaMKII control the balance between activating and inhibitory autophosphorylation.. Elife, 9 [PMID:32149607] |
14. Le TM et al.. (2021) Ex vivo Induction of Apoptotic Mesenchymal Stem Cell by High Hydrostatic Pressure.. Stem Cell Rev Rep, 17 (2): (662-672). [PMID:33128169] |
15. Bukong TN et al.. (2014) Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90.. PLoS Pathog, 10 (10): (e1004424). [PMID:25275643] |
16. Qian L et al.. (2016) Grb7 and Hax1 may colocalize partially to mitochondria in EGF-treated SKBR3 cells and their interaction can affect Caspase3 cleavage of Hax1.. J Mol Recognit, 29 (7): (318-33). [PMID:26869103] |
17. Le TM et al.. (2020) Hydrostatic pressure can induce apoptosis of the skin.. Sci Rep, 10 (17594). [PMID:33077833] |
18. Avril M et al.. (2019) Interplay of Plasmodium falciparum and thrombin in brain endothelial barrier disruption.. Sci Rep, 9 (13142). [PMID:31511575] |
19. Park YH et al.. (2016) Involvement of AMPA Receptor and Its Flip and Flop Isoforms in Retinal Ganglion Cell Death Following Oxygen/Glucose Deprivation.. Invest Ophthalmol Vis Sci, 57 (2): (508-26). [PMID:26868754] |
20. Magerus-Chatinet A & Rieux-Laucat F. (2017) In Vitro Evaluation of the Apoptosis Function in Human Activated T Cells.. Methods Mol Biol, 1557 (33-40). [PMID:28078580] |
21. Nicholls SB et al.. (2011) Mechanism of a genetically encoded dark-to-bright reporter for caspase activity.. J Biol Chem, 286 (28): (24977-86). [PMID:21558267] |
22. Hansel CS et al.. (2019) Nanoneedle-Mediated Stimulation of Cell Mechanotransduction Machinery.. ACS Nano, 13 (3): (2913-2926). [PMID:30829469] |
23. Anderson CJ et al.. (2021) Microbes exploit death-induced nutrient release by gut epithelial cells.. Nature, 596 (7871): (262-267). [PMID:34349263] |
24. Vasilevich AS et al.. (2020) On the correlation between material-induced cell shape and phenotypical response of human mesenchymal stem cells.. Sci Rep, 10 (18988). [PMID:33149200] |
25. Le Vasseur M et al.. (2019) Pannexin 2 Localizes at ER-Mitochondria Contact Sites.. Cancers (Basel), 11 (3): [PMID:30862038] |
26. Jabbari K et al.. (2021) Protein Ligands in the Secretome of CD36+ Fibroblasts Induce Growth Suppression in a Subset of Breast Cancer Cell Lines.. Cancers (Basel), 13 (18): [PMID:34572749] |
27. Yadikar H et al.. (2020) Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization.. PLoS One, 15 (7): (e0224952). [PMID:32692785] |
28. Langsfeld ES et al.. (2015) The Deacetylase Sirtuin 1 Regulates Human Papillomavirus Replication by Modulating Histone Acetylation and Recruitment of DNA Damage Factors NBS1 and Rad51 to Viral Genomes.. PLoS Pathog, 11 (9): (e1005181). [PMID:26405826] |